Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;7(3):283–304. doi: 10.1111/j.1527-3458.2001.tb00200.x

Fluvoxamine as an Adjunctive Agent in Schizophrenia

Henry Silver 1,1,✉
PMCID: PMC6741705  PMID: 11607044

ABSTRACT

Schizophrenia is a common mental disorder that has an early onset and rates high as a cause of medical disability. Antipsychotic agents are the mainstay of treatment but response is often inadequate. Negative symptoms (disturbances in volition, social interaction and affective functions) are particularly difficult to treat and form a major obstacle to rehabilitation. A promising approach to improve response of negative symptoms has been to add a selective serotonin reuptake inhibitor (SSRI) antidepressant to antipsychotic treatment. This review examines evidence pertaining to the efficacy, tolerability, and safety of the SSRI fluvoxamine, combined with antipsychotic agents, in the treatment of negative symptoms in schizophrenia. Important methodological issues, such as differentiating primary and secondary negative symptoms, are discussed. The balance of available evidence indicates that fluvoxamine can improve primary negative symptoms in chronic schizophrenia patients treated with typical antipsychotic s and suggests that it may also do so in some patients treated with clozapine. This combination is generally safe and well tolerated although, as antipsychotic drug concentrations may be elevated, attention to dose and drug monitoring should be considered appropriately. Combination with clozapine may require particular caution because of potential toxicity if serum clozapine levels rise steeply. The fluvoxamine doses effective in augmentation are lower than those usually used to treat depression. Evidence regarding the use of fluvoxamine augmentation to treat phenomena, such as obsessions and aggression, which may be associated with Schizo Prenia, is also examined. An impartant goal of future studies will be to define which patint groups can benefit from combined treatment.

Keywords: Drug‐drug interactions, Fluvoxamine, Negative symptoms‐Pharmacokinetics, Schizophrenia, Selective serotonin reuptake inhibitor (SSRI)

Full Text

The Full Text of this article is available as a PDF (173.7 KB).

References

  • 1. Addington D, Addington J, Atkinson M. A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. Schizophr Res 1996;19:205–212. [DOI] [PubMed] [Google Scholar]
  • 2. Addington D, Addington J, Maticka‐Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 1992;6:201–208. [DOI] [PubMed] [Google Scholar]
  • 3. Addington D, Addington J, Patten S. Depression in people with first‐episode schizophrenia. Br J Psychiatry 1998;172 (Suppl 33): 90–92. [PubMed] [Google Scholar]
  • 4. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990;3:247–251. [DOI] [PubMed] [Google Scholar]
  • 5. Alderman CP, Frith PA. Fluvoxamine‐methadone interaction. Aust NZ J Psychiatry 1999;33:99–101. [DOI] [PubMed] [Google Scholar]
  • 6. Alphs LD, Summerfelt A, Lann H, et al. The negative symptoms assessment: A new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull 1989;25:159–163. [PubMed] [Google Scholar]
  • 7. Andreasen NC. Negative symptoms in schizophrenia: Definition and reliability. Arch Gen Psychiatry 1982;39:789–794. [DOI] [PubMed] [Google Scholar]
  • 8. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City : Univ. of Iowa, 1983. [Google Scholar]
  • 9. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City : Univ. of Iowa, 1984. [Google Scholar]
  • 10. Andreasen NC, Flaum M, Swayze HVW, et al. Positive and negative symptoms in schizophrenia: a critical reappraisal. Arch Gen Psychiatry 1990;47:615–621. [DOI] [PubMed] [Google Scholar]
  • 11. Andreasen NC, Olsen S. Negative vs. positive schizophrenia: Definition and validation. Arch Gen Psychiatry 1982;39:789–794. [DOI] [PubMed] [Google Scholar]
  • 12. Arango C, Kirkpatrick B, Buchanan RW. Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms. J Nerv Ment Dis 2000;188:50–53. [DOI] [PubMed] [Google Scholar]
  • 13. Armstrong SC, Stephans JR. Blood clozapine levels elevated by fluvoxamine: Potential for side effects and lower clozapine dosage. J Clin Psychiatry 1997;58:499. [DOI] [PubMed] [Google Scholar]
  • 14. Arndt S, Andreasen NC, Flaum M, et al. A longitudinal study of symptom dimensions in schizophrenia: Prediction and patterns of change. Arch Gen Psychiatry 1995;52:352–360. [DOI] [PubMed] [Google Scholar]
  • 15. Avenoso A, Spina E, Campo G, et al. Interaction between fluoxetine and haloperidol: Pharmacokinetic and clinical implications. Pharmacol Res 1997;35:335–339. [PubMed] [Google Scholar]
  • 16. Ayuso‐Gutierrez JL, Palazon M, Ayuso‐Mateos JL. Open trial of fluvoxamine in the treatment of bulimia nervosa. Int J Eat Disord 1994;15:245–249. [DOI] [PubMed] [Google Scholar]
  • 17. Barnes TR, Curson DA, Liddle PF, Patel M. The nature and prevalence of depression in chronic schizophrenic in‐patients. Br J Psychiatry 1989;154:486–491. [DOI] [PubMed] [Google Scholar]
  • 18. Bastani JB, Troester MM, Bastani AJ. Serotonin syndrome and fluvoxamine: A case study. Nebr Med J 1996;81:107–109. [PubMed] [Google Scholar]
  • 19. Baynes D, Mulholland C, Cooper SJ, et al. Depressive symptoms in stable chronic schizophrenia: Prevalence and relationship to psychopathology and treatment. Schizophr Res 2000;45:47–56. [DOI] [PubMed] [Google Scholar]
  • 20. Becquemont L, Le Bot MA, Riche C, Beaune P. Influence of fluvoxamine on tacrine metabolism in vitro: Potential implication for the hepatotoxicity in vivo. Fundam Clin Pharmacol 1996;10:156–157. [DOI] [PubMed] [Google Scholar]
  • 21. Becquemont L, Ragueneau I, Le Bot MA, Riche C, Funck‐Brentano C, Jaillon P Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 1997;61:619–627. [DOI] [PubMed] [Google Scholar]
  • 22. Benfield P, Ward A. Fluvoxamine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986;32:313–334. [DOI] [PubMed] [Google Scholar]
  • 23. Berman I, Kalinowski A, Berman SM, Lengua J, Green AI. Obsessive and compulsive symptoms in chronic schizophrenia. Compr Psychiatry 1995;36:6–10. [DOI] [PubMed] [Google Scholar]
  • 24. Bermanzohn PC, Porto L, Arlow PB, Pollack S, Stronger R, Siris SG. Hierarchical diagnosis in chronic schizophrenia: A clinical study of co‐occurring syndromes. Schizophr Bull 2000;26:517–525. [DOI] [PubMed] [Google Scholar]
  • 25. Bertschy G, Baumann P, Eap CB, Baettig D. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit 1994;16:42–45. [DOI] [PubMed] [Google Scholar]
  • 26. Black DW, Monahan P, Gabel J. Fluvoxamine in the treatment of compulsive buying. J Clin Psychiatry 1997;58:159–163. [DOI] [PubMed] [Google Scholar]
  • 27. Bland RC, Newman SC, Orn H. Schizophrenia: Lifetime co‐morbidity in a community sample. Acta Psychiatr Scand 1987;75:383–391. [DOI] [PubMed] [Google Scholar]
  • 28. Bleuler E. Dementia Praecox: or the Group of Schizophrenias Translated by Zinkin J. New York : Int. Univ. Press, 1969. [Google Scholar]
  • 29. Brennan JU, Nui J, Pullen R, et al. Steady state pharmacokinetics of fluvoxamine in young and elderly volunteers [abstract]. Clin Pharmacol Ther 1998;63:164. [Google Scholar]
  • 30. Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 1996;153:1625–1627. [DOI] [PubMed] [Google Scholar]
  • 31. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999;37:177–193. [DOI] [PubMed] [Google Scholar]
  • 32. Carillo JA, Dahl ML, Svensson JO, Alm C, Rodriguez I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYPIA2 activity. Clin Pharmacol Ther 1996;60:183–190. [DOI] [PubMed] [Google Scholar]
  • 33. Carpenter WT, Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schizophr Bull 1985;11:440–452. [DOI] [PubMed] [Google Scholar]
  • 34. Carpenter LL, McDougle CJ, Epperson CN, Price LH. A risk‐benefit assessment of drugs used in the management of obsessive‐compulsive disorder. Drug Safety 1996;15:116–134. [DOI] [PubMed] [Google Scholar]
  • 35. Cases O, Seif I, Grimsby J, et al. Aggressive behavior and altered amounts of brain serotonin and norepine‐phrine in mice lacking MAOA. Science 1995;268 (5218): 1763–1766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Caspi N, Modai I, Barak P, et al. Pindolol augmentation in aggressive schizophrenic patients: A double‐blind cross‐over randomized study. Int Clin Psychopharmacol 2001;In press. [DOI] [PubMed] [Google Scholar]
  • 37. Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, Flood JG. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996;153:820–822. [DOI] [PubMed] [Google Scholar]
  • 38. Chang WH, Augustin B, Lane HY, et al. In‐vitro and in‐vivo evaluation of the drug‐drug interaction between fluvoxamine and clozapine. Psychopharmacology (Berlin) 1999;145:91–98. [DOI] [PubMed] [Google Scholar]
  • 39. Chong SA, Low BL. Treatment of kleptomania with fluvoxamine. Acta Psychiatr Scand 1996;93 (4): 314–315. [DOI] [PubMed] [Google Scholar]
  • 40. Chong SA, Tan CH, Lee HS. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: Two case reports [letter]. J Clin Psychopharmacol 1997;17:68–69. [DOI] [PubMed] [Google Scholar]
  • 41. Claussen V. Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br J Clin Pharma-col 1983;15:349S–355S. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Claussen V, Davies JE, Hunting G, et al. Fluvoxamine, a specific beta‐hydroxytryptamine uptake inhibitor. Br J Pharmacol 1977;60:505–516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Collins AA, Remington G, Coulter K, Birkett K. Depression in schizophrenia: A comparison of three measures. Schizophr Res 1996;20:205–209. [DOI] [PubMed] [Google Scholar]
  • 44. Conus P, Bondolfi G, Eap CB, Macciardi F, Baumann P. Pharmacokinetic fluvoxamine‐clomipramine interaction with favorable therapeutic consequences in therapy‐resistant depressive patients. Pharmacopsychiatry 1996;29:108–110. [DOI] [PubMed] [Google Scholar]
  • 45. Crow TJ. Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 1980;137:383–386. [PubMed] [Google Scholar]
  • 46. Czobor P, Bitter I, Volavka J. Relationship between the Brief Psychiatric Rating Scale and the Scale for Assessment of Negative Symptoms: A study of the correlation and redundancy. Psychiatry Res 1990;36:129–139. [DOI] [PubMed] [Google Scholar]
  • 47. Daniel DG, Randolph C, Jaskiw G, et al. Co‐administration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 1994;14:340–343. [PubMed] [Google Scholar]
  • 48. De Bree, H , van der Schoot JB, Post LC. Fluvoxamine maleate: Disposition in man. Eur J Drug Metab Pharmacokinet 1983;3:175–179. [DOI] [PubMed] [Google Scholar]
  • 49. Demisch K, Demisch L, Nickelsen T, Rieth R. The influence of acute and subchronic administration of various antidepressants on early morning melatonin plasma levels in healthy subjects: Increases following fluvoxamine. J Neural Transm 1987;68:257–270. [DOI] [PubMed] [Google Scholar]
  • 50. de Montigny C, Chaput Y, Blier P. Modification of serotonergic neuron properties by long‐term treatment with serotonin reuptake blockers. J Clin Psychiatry 1990;51(Suppl B): 4–8. [PubMed] [Google Scholar]
  • 51. Dequardo JR, Roberts M. Elevated clozapine levels after fluvoxamine initiation. Am J Psychiatry 1996;153:840–841. [DOI] [PubMed] [Google Scholar]
  • 52. DeVane CL, Gill HS. Clinical pharmacokinetics of fluvoxamine: Applications to dosage regimen design. J Clin Psychiatry 1997;58 (Suppl 5): 7–14. [PubMed] [Google Scholar]
  • 53. DeVane CL, Markowitz JS, Hardesty SJ, Mundy S, Gill HS. Fluvoxamine‐induced theophylline toxicity. Am J Psychiatry 1997;154:1317–1318. [DOI] [PubMed] [Google Scholar]
  • 54. De Vries MH, Raghoebar M, Mathlener IS, van Harten J. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit 1992;14:493–498. [DOI] [PubMed] [Google Scholar]
  • 55. De Wilde JEM, Doogan DP. Fluvoxamine and chlorimipramine in endogenous depression. J Affect Disord 1982;4:249–259. [DOI] [PubMed] [Google Scholar]
  • 56. DuMortier G, Lochu A, Colen de Melo P, et al. Elevated clozapine plasma concentrations after fluvoxamine initiation. Am J Psychiatry 1996;153:738–739. [DOI] [PubMed] [Google Scholar]
  • 57. Durst R, Katz G, Knobler HY. Buspirone augmentation of fluvoxamine in the treatment of kleptomania. J Nerv Ment Dis 1997;185:586–588. [DOI] [PubMed] [Google Scholar]
  • 58. Edwards JG, Inman WH, Wilton L, Pearce GL. Prescription‐event monitoring of 10,401 patients treated with fluvoxamine. Br J Psychiatry 1994;164:387–395. [DOI] [PubMed] [Google Scholar]
  • 59. Edwards J, McGorry PD, Waddell FM, Harrigan SM. Enduring negative symptoms in first‐episode psychosis: Comparison of six methods using follow‐up data. Schizophr Res 1999;40:147–158. [DOI] [PubMed] [Google Scholar]
  • 60. Eisen JL, Beer DA, Pato MT, Venditto TA, Rasmussen SA. Obsessive‐compulsive disorder in patients with schizophrenia or schizoaffective disorder. Am J Psychiatry 1997;154:271–273. [DOI] [PubMed] [Google Scholar]
  • 61. Evins AE, Goff DC. Adjunctive antidepressant drug therapies in the treatment of negative symptoms of schizophrenia. CNS Drugs 1996;2:130–147. [Google Scholar]
  • 62. Fenton WS, McGlashan TH. The prognostic significance of obsessive‐compulsive symptoms in schizophrenia. Am J Psychiatry 1986;143:437–441. [DOI] [PubMed] [Google Scholar]
  • 63. Fenton WS, McGlashan TH. Testing systems for assessment of negative symptoms in schizophrenia. Arch Gen Psychiatry 1992;49:179–184. [DOI] [PubMed] [Google Scholar]
  • 64. Ferslew KE, Hagardorn AN, Harlan GC, McCormick WF. A fatal drug interaction between clozapine and fluoxetine. J Forensic Sci 1998;43:1082–1085. [PubMed] [Google Scholar]
  • 65. Fichter MM, Kruger R, Rief W, Holland R, Dohne J. Fluvoxamine in prevention of relapse in bulimia nervosa: Effects on eating‐specific psychopathology. J Clin Psychopharmacol 1996;16:9–18. [DOI] [PubMed] [Google Scholar]
  • 66. Fichter MM, Leibl C, Kruger R, Rief W. Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa. Pharmacopsychiatry 1997;30:85–92. [DOI] [PubMed] [Google Scholar]
  • 67. Figgit DP, McClellan KJ. Fluvoxamine: An updated review of its use in the management of adults with anxiety disorders. Drugs 2000;60:925–954. [DOI] [PubMed] [Google Scholar]
  • 68. Flament MF, Bisserbe JC. Pharmacologic treatment of obsessive‐compulsive disorder: Comparative studies. J Clin Psychiatry 1997;58 (Suppl 12): 18–22. [PubMed] [Google Scholar]
  • 69. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994;46:35–39. [DOI] [PubMed] [Google Scholar]
  • 70. Goff DC, Midha KK, Sarid‐Segal O, Hubbard JW, Amico E. A placebo‐controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berlin) 1995;117:417–423. [DOI] [PubMed] [Google Scholar]
  • 71. Gonzales FJ. Human cytochromes P450: Problems and prospects. Trends Pharmacol Sci 1992;13:346–352. [DOI] [PubMed] [Google Scholar]
  • 72. Goodman WK, Kozak MJ, Liebowitz M, White KL. Treatment of obsessive‐compulsive disorder with flu‐voxamine: A multicentre, double‐blind, placebo‐controlled trial. Int Clin Psychopharmacol 1996;11:21–29. [PubMed] [Google Scholar]
  • 73. Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive‐compulsive disorder. A double‐blind comparison with placebo. Arch Gen Psychiatry 1989;46:36–44. [DOI] [PubMed] [Google Scholar]
  • 74. Goodman WK, Price LH, Rasmussen SA, et al. The Yale‐Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989;46:1006–1011. [DOI] [PubMed] [Google Scholar]
  • 75. Goodman WK, Ward H, Kablinger A, Murphy T. Fluvoxamine in the treatment of obsessive‐compulsive disorder and related conditions. J Clin Psychiatry 1997;58 (Suppl 5): 32–49. [PubMed] [Google Scholar]
  • 76. Greist HJ, Jemike MA, Robinson D, et al. Efficacy of fluvoxamine in obsessive‐compulsive disorder: Results of a multicentre double blind, placebo‐controlled trial. Eur J Clin Res 1995;7:195–204. [Google Scholar]
  • 77. Hamilton M. The classification of depressive illness. Br J Psychiatry 1970;117:348–349. [PubMed] [Google Scholar]
  • 78. Hartter S, Grozinger M, Weigmann H, Roschke J, Hiemke C. Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther 2000;67:1–6. [DOI] [PubMed] [Google Scholar]
  • 79. Hartter S, Wang X, Weigmann H, et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol 2001;21:In press. [DOI] [PubMed] [Google Scholar]
  • 80. Hartter S, Wetzel H, Hammes E, Torksadeh M, Hiemke C. Non‐linear pharmacokinetics of fluvoxamine and gender differences. Ther Drug Monit 1998;20:446–449. [DOI] [PubMed] [Google Scholar]
  • 81. Hartter S. Wetzel H, Hammes E, Torkzadeh M, Hiemke C. Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial. Pharmacopsychiatry 1998;31:199–200. [DOI] [PubMed] [Google Scholar]
  • 82. Harvey PD, Putman KM, Davidson M, et al. Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non‐Kraepelinian chronic schizophrenic patients. Psychiatry Res 1991;38:285–292. [DOI] [PubMed] [Google Scholar]
  • 83. Heeringa M, Beurskens R, Schouten W, Verduijn MM. Elevated plasma levels of clozapine after concomitant use of fluvoxamine. Pharm World Sci 1999;21:243–244. [DOI] [PubMed] [Google Scholar]
  • 84. Heinz A, Knable MB, Coppola R, et al. Psychomotor slowing, negative symptoms and dopamine receptor availability — an IBZM SPECT study in neuroleptic‐treated and drug‐free schizophrenic patients. Schizophr Res 1998;31:19–26. [DOI] [PubMed] [Google Scholar]
  • 85. Hemeryck A, De Vriendt C, Belpaire FM. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: In vitro studies with tolbutamide and (S)‐warfarin using human liver microsomes. Eur J Clin Pharmacol 1999;54:947–951. [DOI] [PubMed] [Google Scholar]
  • 86. Hernandez L, Baptista T, Hoebel BG. Neurochemical effects of chronic haloperidol and lithium assessed by brain microdialysis in rats. Prog Neuropsychopharmacol Biol Psychiatry 1990;14 (Suppl): S17–S35. [DOI] [PubMed] [Google Scholar]
  • 87. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000;85:11–28. [DOI] [PubMed] [Google Scholar]
  • 88. Hiemke C, Weigmann H, Hartter S, Dahmen N, Wetzel H, Muller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994;14:279–281. [PubMed] [Google Scholar]
  • 89. Hinze‐Selch D, Deuschle M, Weber B, Heuser I, Pollmacher T. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology (Berlin) 2000;149:163–169. [DOI] [PubMed] [Google Scholar]
  • 90. Hirsch SR, Jolley AG, Barnes TR, et al. Dysphoric and depressive symptoms in chronic schizophrenia. Schizophr Res 1989;2:259–264. [DOI] [PubMed] [Google Scholar]
  • 91. Hollander E, Benzaquen SD. The obsessive‐compulsive spectrum disorders. Int Rev Psychiatry 1997;9:99–109. [Google Scholar]
  • 92. Hollander E, Cohen L, Simeon D, Rosen J, DeCaria C, Stein DJ. Fluvoxamine treatment of body dysmorphic disorder. J Clin Psychopharmacol 1994;14:75–77. [PubMed] [Google Scholar]
  • 93. Hollander E, DeCaria CM, Finkell JN, Begaz T, Wong CM, Cartwright C. A randomized double‐blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry 2000;47:813–817. [DOI] [PubMed] [Google Scholar]
  • 94. Hollander E, DeCaria CM, Mari E, et al. Short‐term single‐blind fluvoxamine treatment of pathological gambling. Am J Psychiatry 1998;155:1781–1783. [DOI] [PubMed] [Google Scholar]
  • 95. Hudson JI, McElroy SL, Raymond NC, et al. Fluvoxamine in the treatment of binge‐eating disorder: A multicenter placebo‐controlled, double‐blind trial. Am J Psychiatry 1998;155:1756–1762. [DOI] [PubMed] [Google Scholar]
  • 96. Hurst M, Lamb HM. Fluoxetine: A review of its use in anxiety disorders and mixed anxiety and depression. CNS Drugs 2000;14:51–80. [Google Scholar]
  • 97. Hyttel J. Comparative pharmacology of selective serotonin reuptake inhibitors (SSRIs). Nord J Psychiatry 1993;47 (Suppl): 5–12. [Google Scholar]
  • 98. Iager A, Kirsch D, Wyatt R. Anegative symptom rating scale. Psychiatry Res 1986;16:27–36. [DOI] [PubMed] [Google Scholar]
  • 99. Invernizzi R, Pozzi L, Samanin R. Further studies on the effects of chronic clozapine on regional extracellular dopamine levels in the brain of conscious rats. Brain Res 1995;670:165–168. [DOI] [PubMed] [Google Scholar]
  • 100. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K. Dose‐dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73–78. [DOI] [PubMed] [Google Scholar]
  • 101. Jeppesen U, Loft S, Poulsen HE, Brosen K. A fluvoxamine‐caffeine interaction study. Pharmacogenetics 1996;6:213–222. [DOI] [PubMed] [Google Scholar]
  • 102. Jeppesen U, Rasmussen BB, Brosen K. Fluvoxamine inhibits the CYP2C19‐catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 1997;62:279–286. [DOI] [PubMed] [Google Scholar]
  • 103. Kane JM, Woerner M, Sarantakos S. Depot neuroleptics: A comparative review of standard, intermediate, and low dose regimen. J Clin Psychiatry 1986;47 (Suppl 5): S30–S33. [PubMed] [Google Scholar]
  • 104. Kasper S, Dotsch M, Kick H, Vieira A, Moller HJ. Plasma concentrations of fluvoxamine and maprotiline in major depression — implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol 1993;3:13–21. [DOI] [PubMed] [Google Scholar]
  • 105. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizoprhenics. Psychiatry Res 1987;23:99–110. [DOI] [PubMed] [Google Scholar]
  • 106. Kirkpatrick B, Buchanan R, McKenney P. The schedule for the deficit syndrome: An instrument for research in schizophrenia. Psychiatry Res 1989;30:119–123. [DOI] [PubMed] [Google Scholar]
  • 107. Koponen HJ, Leinonen E, Lepola U. Fluvoxamine increases the clozapine serum levels significantly. Eur Neuropsychopharmacol 1996;6:69–71. [DOI] [PubMed] [Google Scholar]
  • 108. Kuck J, Zisook S, Moranville JT, et al. Negative symptomatology in schizophrenic outpatients. J Nerv Ment Dis 1992;180:510–515. [DOI] [PubMed] [Google Scholar]
  • 109. Kulhara P, Avasthi A, Chadda R, et al. Negative and depressive symptoms in schizophrenia. Br J Psychiatry 1989;154:207–211. [DOI] [PubMed] [Google Scholar]
  • 110. Lammers CH, Deuschle M, Weigmann H, et al. Co‐administration of clozapine and fluvoxamine in psychotic patients — clinical experience. Pharmacopsychiatry 1999;32:76–77. [DOI] [PubMed] [Google Scholar]
  • 111. Lee MS, Kim YK, Lee SK, Suh KY. A double‐blind study of adjunctive sertraline in haloperidol‐stabilized patients with chronic schizophrenia. J Clin Psychopharmacol 1998;18:399–403. [DOI] [PubMed] [Google Scholar]
  • 112. Lenzi A, Raffaelli S, Marazziti D. Serotonin syndrome‐like symptoms in a patient with obsessive‐compulsive disorder, following inappropriate increase in fluvoxamine dosage. Pharmacopsychiatry 1993;26:100–101. [DOI] [PubMed] [Google Scholar]
  • 113. Leonard BE. Movement disorders and abuse potential of the selective serotonin reuptake inhibitors. Hum Psychopharmacol 1999;14:1–6. [Google Scholar]
  • 114. Li Q, Levy AD, Cabrera TM, Brownfield MS, Battaglia G, Van de Kar LD. Long‐term fluoxetine, but not desipramine, inhibits the ACTH and oxytocin responses to the 5‐HT1A agonist, 8‐OH‐DPAT, in male rats. Brain Res 1993;630:148–156. [DOI] [PubMed] [Google Scholar]
  • 115. Li XM, Perry KW, Wong DT, Bymaster FP. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berlin) 1998;136:153–161. [DOI] [PubMed] [Google Scholar]
  • 116. Lu ML, Lane HY, Chen KP, Jann MW, Su MH, Chang WH. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 2000;61:594–599. [DOI] [PubMed] [Google Scholar]
  • 117. Maguire K, Cheung P, Crowley K, Norman T, Schweitzer I, Burrows G. Aggressive behaviour and platelet 3H‐paroxetine binding in schizophrenia. Schizophr Res 1997;23:61–67. [DOI] [PubMed] [Google Scholar]
  • 118. Marder SR, Van Putten T, Mintz J, et al. Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 1984;41:1025–1029. [DOI] [PubMed] [Google Scholar]
  • 119. Markowitz JS, Gill HS, Lavia M, Brewerton TD, DeVane CL. Fluvoxamine‐clozapine dose‐dependent interaction. Can J Psychiatry 1996;41:670–671. [DOI] [PubMed] [Google Scholar]
  • 120. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double‐blind, placebo‐controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996;53:1001–1008. [DOI] [PubMed] [Google Scholar]
  • 121. Melis M, Diana M, Gessa GL. Clozapine potently stimulates mesocortical dopamine neurons. Eur J Pharmacol 1999;366:R11–R13. [DOI] [PubMed] [Google Scholar]
  • 122. Meltzer HY. The importance of serotonin‐dopamine interactions in the action of clozapine. Br J Psychiatry 1992;160 (Suppl 17): 22–29. [PubMed] [Google Scholar]
  • 123. Miljkovic BR, Pokrajac M, Timotijevic I, Varagic V. The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine‐lithium therapy. Int Clin Psychopharmacol 1997;12:207–212. [PubMed] [Google Scholar]
  • 124. Modai I, Gibel A, Rauchverger B, Ritsner M, Klein E, Ben Shachar D. Paroxetine binding in aggressive schizophrenic patients. Psychiatry Res 2000;94:77–81. [DOI] [PubMed] [Google Scholar]
  • 125. Moller H. The negative component in schizophrenia. Acta Psychiatr Scand 1995;91:11–14. [DOI] [PubMed] [Google Scholar]
  • 126. Moller HJ, van Praag HM, Aufdembrinke B, et al. Negative symptoms in schizophrenia: Considerations for clinical trials. Working group on negative symptoms in schizophrenia. Psychopharmacology (Berlin) 1994;115:221–228. [DOI] [PubMed] [Google Scholar]
  • 127. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–389. [DOI] [PubMed] [Google Scholar]
  • 128. Mortimer AM, Lund CE, McKenna PJ. The positive negative dichotomy in schizophrenia. Br J Psychiatry 1990;157:41–49. [DOI] [PubMed] [Google Scholar]
  • 129. Narita N, Hashimoto K, Tonitska S, et al. Interactions of selective serotonin reuptake inhibition with subtypes of 6 receptors in rat brain. Eur J Pharmacol 1996;307:117–119. [DOI] [PubMed] [Google Scholar]
  • 130. Newcomer JW, Faustman WO, Yeh W, et al. Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia. Psychiatry Res 1989;31:243–250. [DOI] [PubMed] [Google Scholar]
  • 131. Ochs HR, Greenblatt DJ, Verburg‐Ochs B, Labedski L. Chronic treatment with fluvoxamine, clovoxamine, and placebo: Interaction with digoxin and effects on sleep and alertness. J Clin Pharmacol 1989;29:91–95. [DOI] [PubMed] [Google Scholar]
  • 132. Olesen OV, Linnet K. Fluvoxamine‐Clozapine drug interaction: Inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol 2000;20:35–42. [DOI] [PubMed] [Google Scholar]
  • 133. Olivier B, Mos J, van Oorschot R, Hen R. Serotonin receptors and animal models of aggressive behavior. Pharmacopsychiatry 1995;28 (Suppl 2): 80–90. [DOI] [PubMed] [Google Scholar]
  • 134. Overall JE, Gorham DR. The brief psychiatric rating scale (BPRS). Psychol Rep 1962;10:799–812. [Google Scholar]
  • 135. Overmars H, Scherpenisse PM, Post LC. Fluvoxamine maleate: Metabolism in man. Eur J Drug Metab Pharmacokinet 1983;8:269–280. [DOI] [PubMed] [Google Scholar]
  • 136. Palmer KJ, Benfield P. Fluvoxamine: An overview of its pharmacological properties and review of its therapeutic potential in non‐depressive disorders. CNSD rugs 1994;1:57–87. [Google Scholar]
  • 137. Peralta V, Cuesta MJ, Martinez‐Larrea A, Serrano JF. Differentiating primary from secondary negative symptoms in schizophrenia: A study of neuroleptic‐naive patients before and after treatment. Am J Psychiatry 2000;157:1461–1466. [DOI] [PubMed] [Google Scholar]
  • 138. Perse TL, Greist JH, Jefferson JW, Rosenfeld R, Dar R. Fluvoxamine treatment of obsessive‐compulsive disorder. Am J Psychiatry 1987;144:1543–1548. [DOI] [PubMed] [Google Scholar]
  • 139. Perucca E, Gatti G, Cipolla G, et al. Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994;56:471–476. [DOI] [PubMed] [Google Scholar]
  • 140. Phillips KA, Dwight MM, McElroy SL. Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry 1998;59:165–171. [DOI] [PubMed] [Google Scholar]
  • 141. Pogue‐Geile MF, Harrow M. Negative and positive symptoms in schizophrenia and depression: A follow‐up. Schizophr Bull 1984;10:371–387. [DOI] [PubMed] [Google Scholar]
  • 142. Pollack MH. Psychopharmacology update. Panic disorder: A treatment update. J Clin Psychiatry 1997;58:38–40. 9078993 [Google Scholar]
  • 143. Poyurovsky M, Fuchs C, Weizman A. Obsessive‐compulsive disorder in patients with first‐episode schizophrenia. Am J Psychiatry 1999;156:1998–2000. [DOI] [PubMed] [Google Scholar]
  • 144. Poyurovsky M, Hermesh H, Weizman A. Fluvoxamine treatment in clozapine‐induced obsessive‐compulsive symptoms in schizophrenic patients. Clin Neuropharmacol 1996;19:305–313. [DOI] [PubMed] [Google Scholar]
  • 145. Poyurovsky M, Isakov V, Hromnikov S, et al. Fluvoxamine treatment of obsessive‐compulsive symptoms in schizophrenic patients: An add‐on open study. Int Clin Psychopharmacol 1999;14:95–100. [DOI] [PubMed] [Google Scholar]
  • 146. Rasmussen BB, Nielsen TL, Brosen K. Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Pharmacol Toxicol 1998;83:240–245. [DOI] [PubMed] [Google Scholar]
  • 147. Rasmussen BB, Jeppesen U, Gaist D, Brosen K. Griseofulvin and fluvoxamine interactions with the metab‐olismoftheophylline. Ther Drug Monit 1997;19:56–62. [DOI] [PubMed] [Google Scholar]
  • 148. Remington G, Chong SA, Kapur S. Distinguishing change in primary and secondary negative symptoms. Am J Psychiatry 1999;156:974–975. [DOI] [PubMed] [Google Scholar]
  • 149. Reznik I, Sirota P. Obsessive and compulsive symptoms in schizophrenia: A randomized controlled trial with fluvoxamine and neuroleptics J Clin Psychopharmacol 2000;20:410–416. [DOI] [PubMed] [Google Scholar]
  • 150. Richelson E. Pharmacology of antidepressants — characteristics of the ideal drug. Mayo Clin Proc 1994;69:1069–1081. [DOI] [PubMed] [Google Scholar]
  • 151. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH. 5‐HT(1A) receptor activation contributes to ziprasidone‐induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 2000;48:229–237. [DOI] [PubMed] [Google Scholar]
  • 152. Salokangas RK, Saarijarvi S, Taiminen T, et al. Citalopram as an adjuvant in chronic schizophrenia: A double‐blind placebo‐controlled study. Acta Psychiatr Scand 1996;94:175–180. [DOI] [PubMed] [Google Scholar]
  • 153. Seifritz E, Holsboer‐Trachsler E, Hemmeter U, Eap CB, Baumann P. Increased trimipramine plasma levels during fluvoxamine comedication. Eur Neuropsychopharmacol 1994;4:15–20. [DOI] [PubMed] [Google Scholar]
  • 154. Shen WW. The metabolism of psychoactive drugs: A review of enzymatic biotransformation and inhibition. Biol Psychiatry 1997;31:814–826. [DOI] [PubMed] [Google Scholar]
  • 155. Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: A placebo‐controlled study. Int Clin Psychopharmacol 2000;15:257–261. [DOI] [PubMed] [Google Scholar]
  • 156. Silver H, Barash I, Odnopozov N, Jahjah N, Mizruhin A. Melatonin secretion during fluvoxamine treatment in medicated chronic schizophrenic patients: Evidence for the development of tolerance to selective serotonin re‐uptake inhibitor. Biol Psychiatry 1996;40:75–77. [DOI] [PubMed] [Google Scholar]
  • 157. Silver H, Barash I, Shmugliakov N, Odnosporov N. The effect of chronic fluvoxamine treatment on overnight melatonin secretion in medicated chronic schizophrenic patients. Hum Psychopharmacol 1997;12:21–25. [Google Scholar]
  • 158. Silver H, Jahjah N, Kushnir M. Psychotic symptoms in schizophrenics during chronic fluvoxamine treatment. A report of two cases. Schizophr Res 1995;16:77–79. [DOI] [PubMed] [Google Scholar]
  • 159. Silver H, Kaplan A, Jahjah N. Fluvoxamine augmentation in clozapine resistant schizophrenia. Am J Psychiatry 1995;152:1098. [DOI] [PubMed] [Google Scholar]
  • 160. Silver H, Kaplan A, Kushnir M. Fluvoxamine augmentation in chronic schizophrenia: An open exploratory study. Hum Psychopharmacol 1995;10:59–63. [Google Scholar]
  • 161. Silver H, Kushnir M. Treatment of aggression in schizophrenia. Am J Psychiatry 1998;155:1298. [DOI] [PubMed] [Google Scholar]
  • 162. Silver H, Kushnir M, Kaplan A. Fluvoxamine augmentation in clozapine resistant schizophrenia. An open pilot study. Biol Psychiatry 1996;40:671–674. [DOI] [PubMed] [Google Scholar]
  • 163. Silver H, Lerer B. Psychopathological dimensions in schizophrenia In: Studies in Psychology. Festschrift in Honour of S Kugelmass. Ben Shachar D, Lieblich A, Eds. Jerusalem : Magnes Press, 1995. [Google Scholar]
  • 164. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia. An add‐on double blind placebo controlled study. Biol Psychiatry 1992;31:698–704. [DOI] [PubMed] [Google Scholar]
  • 165. Silver H, Odnopozov N, Jahjah N, Barash I. Chronic fluvoxamine treatment reduces platelet MAO activity in medicated schizophrenics. Hum Psychopharmacol 1995;10:321–326. [Google Scholar]
  • 166. Silver H, Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia. J Clin Psychopharmacol 1998;18:208–211. [DOI] [PubMed] [Google Scholar]
  • 167. Silver H, Youdim MB. MAO‐A and MAO‐B activities in rat striatum, frontal cortex and liver are long‐term treatment with fluvoxamine and desipramine. Eur Neuropsychopharmacol 2000;182:1184–1190. [DOI] [PubMed] [Google Scholar]
  • 168. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212 (Suppl): 11–19. [DOI] [PubMed] [Google Scholar]
  • 169. Siris SG. Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. Br J Psychiatry 1993;163 (Suppl 22): 66–78. [PubMed] [Google Scholar]
  • 170. Siris S. Diagnosis of secondary depression in schizophrenia: Implications for DSM‐IV. Schizophrenia Bull 1991;17:75–97. [DOI] [PubMed] [Google Scholar]
  • 171. Siris SG, Adan F, Cohen M, Mandeli J, Aronson A, Casey E. Postpsychotic depression and negative symptoms: An investigation of syndromal overlap. Am J Psychiatry 1988;145:1532–1537. [DOI] [PubMed] [Google Scholar]
  • 172. Siris SC, Bermanzohhn PC, Gonzalez A, et al. The use of antidepressants for negative symptoms in a subset of schizophrenic patients. Psychopharmacol Bull 1991;27:331–335. [PubMed] [Google Scholar]
  • 173. Skene DJ, Bojkowski CJ, Arendt J. Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans. Br J Clin Pharmacol 1994;37:181–186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 174. Sommers A. Negative symptoms”: Conceptual and methodological problems. Schizophr Bull 1985;11:364–379. [DOI] [PubMed] [Google Scholar]
  • 175. Spigset O. Are adverse drug reactions attributed to fluvoxamine caused by concomitant intake of caffeine Eur J Clin Pharmacol 1998;54:665–666. [DOI] [PubMed] [Google Scholar]
  • 176. Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995;58:399–403. [DOI] [PubMed] [Google Scholar]
  • 177. Spigset O, Granberg K, Hagg S, Soderstrom E, Carleborg L, Dahlqvist R. Non‐linear fluvoxamine disposition and relation to some CYP activities. Eur J Clin Pharmacol 1997;52(Suppl): A172. [Google Scholar]
  • 178. Spina E, Avenoso A, Facciola G, et al. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol 1998;13:141–145. [DOI] [PubMed] [Google Scholar]
  • 179. Spina E, De Domenico P, Ruello C, et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 1994;9:281–285. [DOI] [PubMed] [Google Scholar]
  • 180. Spina E, Pollicino AM, Avenoso A, Campo GM, Caputi AP. Fluvoxamine‐induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. Int J Clin Pharmacol Res 1993;13:167–171. [PubMed] [Google Scholar]
  • 181. Stanley MA, Breckenridge JK, Swann AC, Freeman EB, Reich L. Fluvoxamine treatment of trichotillo‐mania. J Clin Psychopharmacol 1997;17:278–283. [DOI] [PubMed] [Google Scholar]
  • 182. Strauss WL, Layton ME, Hayes CE, Dager SR. 19T magnetic resonance spectroscopy investigation in vivo of acute and steady‐state brain fluvoxamine levels in obsessive‐compulsive disorder. Am J Psychiatry 1997;154:516–522. [DOI] [PubMed] [Google Scholar]
  • 183. Szegedi A, Anghelescu I, Wiesner J, et al. Addition of low‐dose fluvoxamine to low‐dose clozapine mono‐therapy in schizophrenia: Drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 1999;32:148–153. [DOI] [PubMed] [Google Scholar]
  • 184. Szegedi A, Wiesner J, Hiemke C. Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J Clin Psychopharmacol 1995;15:141–143. [DOI] [PubMed] [Google Scholar]
  • 185. Thiemann S, Csernansky J, Berger P. Rating scales in research: The case of negative symptoms. Psychiatry Res 1987;20:47–55. [DOI] [PubMed] [Google Scholar]
  • 186. Van DenBrekel AM, Harrington L. Toxic effects of theophylline caused by fluvoxamine. CMAJ 1994;151:1289–1290. [PMC free article] [PubMed] [Google Scholar]
  • 187. Van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1995;29(Suppl 1): 1–9. [DOI] [PubMed] [Google Scholar]
  • 188. Van Harten J, Duebier J, Devissagner JP, et al. Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single‐dose administration. Clin Pharmacokinet 1993;24:177–182. [DOI] [PubMed] [Google Scholar]
  • 189. Van Harten J, Lonnebo A, Grahnen A. Pharmacokinetics of fluvoxamine after intravenous and oral administration. Neuropsychopharmacology 1994;10:104S. [Google Scholar]
  • 190. Van Putten T, May PRA. Akinetic depression” in schizophrenia. Arch Gen Psychiatry 1978;35:1101–1107. [DOI] [PubMed] [Google Scholar]
  • 191. Vandel P, Bonin B, Bertschy G. Observations of the interaction between tricyclic antidepressants and fluvoxamine in poor metabolizers of dextromethorphan and mephenytoin. Therapie 1997;52:74–76. [PubMed] [Google Scholar]
  • 192. Vartiainen H, Tiihonen J, Putkonen A, et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 1995;91:348–351. [DOI] [PubMed] [Google Scholar]
  • 193. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125–131. [DOI] [PubMed] [Google Scholar]
  • 194. Walczak D, Apter JT, Halikas JA, et al. The oral dose‐effect relationship for fluvoxamine: A fixed‐dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry 1996;8:139–151. [DOI] [PubMed] [Google Scholar]
  • 195. Wagner W, Zaborny BA, Gray TE. Fluvoxamine. A review of its safety profile in world‐wide studies. Int Clin Psychopharmacol 1994;9:223–227. [DOI] [PubMed] [Google Scholar]
  • 196. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660–669. [DOI] [PubMed] [Google Scholar]
  • 197. Weinberger DR, Berman KF. Prefrontal function in schizophrenia: Confounds and controversies. Philos Trans R Soc Lond B Biol Sci 1996;29:351 1495–1503. [DOI] [PubMed] [Google Scholar]
  • 198. Wetzel H, Anghelescu I, Szegedi A, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998;18:2–9. [DOI] [PubMed] [Google Scholar]
  • 199. Xu ZH, Xie HG, Zhou HH. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 1996;42:518–521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 200. Yadid G, Pacak K, Kopin IJ, Goldstein DS. Endogenous serotonin stimulates striatal dopamine release in conscious rats. J Pharmacol Exp Ther 1994;270:1158–1165. [PubMed] [Google Scholar]
  • 201. Zhang W, Perry KW, Wong DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000;23:250–262. [DOI] [PubMed] [Google Scholar]
  • 202. Zisook S, McAdams LA, Kuck J, et al. Depressive symptoms in schizophrenia. Am J Psychiatry 1999;156:1736–1743. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES